Navigation Links
Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus
Date:5/19/2008

Interim results from a nationwide clinical trial led by a University of North Carolina at Chapel Hill researcher suggest that radiofrequency ablation is an effective treatment for dysplasia in people with Barretts esophagus, a condition that can lead to deadly gastrointestinal cancer.

The interim results show there is a substantial difference between treatment with radiofrequency ablation and a placebo or sham treatment, said Dr. Nicholas Shaheen, principal investigator of the study and director of UNCs Center for Esophageal Diseases and Swallowing. Its a strongly positive finding.

Shaheen, who is also an associate professor of medicine and epidemiology in UNCs Schools of Medicine and Public Health, presented the results Monday, May 19 at the annual Digestive Disease Week meeting in San Diego.

Barretts esophagus is a condition in which repeated acid reflux causes the cells that normally line the esophagus to be replaced by a different type of cell, similar to those normally found in the intestines. This process is called intestinal metaplasia. By itself Barretts is not a life-threatening problem, but a small percentage of people with Barretts will develop esophageal adenocarcinoma, an especially deadly form of cancer.

Radiofrequency ablation, a non-invasive technique that uses thermal energy, or heat, to destroy cells, is very effective at destroying abnormal cells in the esophagus. The new UNC-led study is the first randomized trial to evaluate radiofrequency ablation for treating dysplasia, a more advanced stage of Barretts esophagus in which the abnormal cells acquire precancerous traits.

The radiofrequency ablation system used in the study uses thermal energy provided by a set of electromagnetic coils on the surface of a balloon, Shaheen said. The balloon is placed in the area of the esophagus where the offending cells are and the balloon is inflated. Energy is then passed through the electromagnetic coils and, because we know how far apart the coils are spaced and how much energy is being put through them, we get a very reliable depth of burn, such that you can kill the abnormal cells on the inner surface without damaging the whole organ.

In the study to date, 127 people were randomized to receive either radiofrequency ablation or a simulated, sham version of the procedure at one of 19 participating medical centers. Among those who received radiofrequency ablation, 85 percent were free of dysplasia 12 months after treatment. Seventy-four percent had no evidence of Barretts at all in their biopsies. In comparison, none that received sham treatment were free of Barretts.


'/>"/>

Contact: Stephanie Crayton
scrayton@med.unc.edu
919-966-2860
University of North Carolina at Chapel Hill
Source:Eurekalert

Related medicine news :

1. BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology
2. ATS Medical Announces First Frontiers in Cryoablation Symposium
3. AtriCures Coolrail(TM) Linear Ablation Pen Receives FDA 510(k) Clearance
4. St. Davids Medical Center First in Texas to Implement Visually Guided Catheter Ablation for Atrial Fibrillation
5. MedWaves, Inc. Announces Receipt of United States Food and Drug Administration 510k Clearance to Market Its Patented Microwave Coagulation/Ablation System
6. Speedy Procedures Demonstrate Excitement and Continued Interest in Novel Multi-Electrode Ablation System
7. Endocare Announces That National Cancer Institute to Sponsor Study Comparing Cryoablation to Radiation Therapy for Pain Relief in Bone Cancer Patients
8. Cryoablation continues to show good results for kidney cancer patients
9. Medicare Sets Physician Payment Rate for Percutaneous Kidney Cryoablation
10. Medicare Increases 2008 Hospital Reimbursement Rates for Cryoablation Treatments of Prostate Cancer
11. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Ron ... an option to senior, upper-level executives speaking at a business luncheon today, "It ... high-level executive is an asset to be fully realized and activated by the ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a ... Reward” is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible ... we returned to our cars, my sister-in-law invited us to come over before the ...
(Date:9/25/2017)... September 25, 2017 - Orlando, FL, Microsoft Ignite Conference (PRWEB) , ... ... ... Hosts, Inc . announced today that they have teamed up to deliver Netmail’s Hadron ... on-demand service from a HIPAA/HITRUST compliant Azure Cloud. Netmail will be demo-ing their Hadron ...
(Date:9/25/2017)... ... ... Ash Borers kill Ash trees in as little as 1-3 years. The signs ... by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in ... signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
(Date:9/24/2017)... & Caicos Islands, BWI (PRWEB) , ... September 25, 2017 , ... ... to announce the resort is re-opening on October 1st. And, throughout the month ... three bedroom oceanfront rentals. , Hurricane Irma and Maria have passed and damage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: